Berkshire executives Buffett and Greg Abel are linked to a larger stake in DaVita than in any other portfolio company, according to a market analysis

A Yahoo Finance analysis published Aug. 27 highlighted a lesser-known pattern inside Berkshire Hathaway’s stock lineup: the company’s two top leaders, Warren Buffett and Greg Abel, are connected to a bigger percentage stake in one specific Berkshire holding than they are in any other. The report frames the finding as a surprise because the answer is not Apple and not American Express, even though those names are often associated with Berkshire’s best-known investments.

The analysis points readers toward DaVita, the kidney-care and dialysis services provider, as the company that fits the “hint” in the title. DaVita is widely recognized as a long-time Berkshire holding, but the new emphasis is on the relative size of the leaders’ proportional stakes versus other Berkshire portfolio companies.

In the article’s framing, the key point is not simply that DaVita sits in Berkshire’s portfolio, but that Buffett and Abel are tied to a larger share of the underlying company than in other holdings. Such leader-specific comparisons typically rely on how much of a target company’s shares are attributed to those individuals, not just on what Berkshire owns overall.

Because the post is a market-news style recap rather than a primary filing or direct quote from Berkshire, it does not lay out a detailed methodology in the text available here. That means the exact mechanics of the comparison, including how the “percentage” is calculated and which disclosed accounts are counted, are not verifiable from the excerpt we have.

For Apple investors and the broader technology sector, the practical takeaway is modest but telling. Berkshire’s most famous technology exposure often centers on Apple, yet this report suggests that when you shift from total portfolio presence to leader-specific proportional exposure, the top answer can move away from the most visible megacap names.

For DaVita, the context is clearer in general terms: it operates in a specialized healthcare services segment with a recurring demand profile tied to chronic kidney disease treatment. When Berkshire leadership appears more concentrated in a single holding on a proportional basis, market watchers typically interpret it as a vote of confidence in the business durability, even if it is not an explicit announcement of near-term trading intent.

Still, viewers should be cautious about reading too much into the leaders’ proportional stake without the underlying calculation and without any additional disclosure. The post does not indicate whether Berkshire leadership intends to change its approach, nor does it provide company fundamentals or new guidance from DaVita itself.

What to watch next is whether Berkshire’s next major disclosure cycle continues to show a similar leader-specific concentration in DaVita, and whether any corporate updates from DaVita or Berkshire help explain the investment rationale. Until then, the analysis stands primarily as a portfolio trivia finding with implications for how leadership exposure can differ from headline holdings.